At Clarent Biopharma, we're developing a portfolio of therapeutic peptides targeting inflammatory and injury-associated pathways.
CBP-0276 achieved its primary endpoint in a Phase 2 clinical study, providing human proof-of-concept for its mechanism of immune modulation.
Clarent applies precision chemistry to develop medicines that modulate inflammatory and tissue injury pathways.
A new clarity in immune modulation
CBP-0276
Designed to modulate rather than suppress immune activity. An approach intended to control pathologic inflammation while maintaining normal host defense mechanisms.
Targeted immune control with clinical-stage precision
The peptide demonstrates very high potency against its biological targets, with activity in the picomolar to femtomolar range. CBP-0276 is orally bioavailable and also suitable for intravenous administration, providing flexibility in clinical and therapeutic use.
Clinically tolerated and manufactured at scale
The molecule has been manufactured under current Good Manufacturing Practice (cGMP) conditions at kilogram scale and has demonstrated a favorable tolerability profile in clinical and preclinical evaluations to date.
For those advancing science with purpose, precision, and integrity, we’re listening
Clarent Biopharma welcomes strategic partners to support development and commercialization of CBP-0276 and related peptide programs across multiple therapeutic areas.
By contacting us, you agree to our Privacy Policy.